31 results about "Streptococcus agalactiae" patented technology

The invention relates to the technical field of aquaculture, in particular to nile tilapia ferritin, a preparation method and application thereof and a bacteriostatic agent. The amino acid sequence of the nile tilapia ferritin is as shown in SEQ ID No.1, and the nile tilapia ferritin inhibits streptococcus agalactiae and / or aeromonas hydrophila. The invention provides Nile tilapia ferritin, and in-vitro experiments prove that the recombinant protein can effectively inhibit proliferation of pathogenic bacteria. A further in-vivo experiment research result shows that the ferritin heavy chain (Nile tilapia ferritin) has important functions of inhibiting pathogenic bacterium proliferation and improving the survival rate of an organism, and plays an important role in immune protection of the organism.

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

The application discloses a kind of fluorescence colorimetric double-mode detection streptococcus agalactiae without aerosol pollution method, comprising the following steps: (1) strain culture and DNA extraction;(2) the combination of UDG and LAMP;(3) UDG-LAMP-CRISPR fluorescence mode detection system;(4) colorimetric mode detection system: read image RGB value in G value, G value significantly increases, and it is positive result.This patent innovatively combines UDG, LAMP, CRISPR and G4, introduces connection probe to realize "fluorescence-colorimetric" single system double-mode detection.The two detection modes of the detection platform can be freely split or combined, and can meet the needs of different detection environments.By combining UDG system and LAMP technology, aerosol pollution possibly carried in amplification process is avoided.Connection probe is introduced, CRISPR fluorescence detection is combined with G4 colorimetric detection, a detection system with "fluorescence-colorimetric" two detection modes is established, which is used for quantitative identification and cross verification of streptococcus agalactiae.

The application discloses a bocachito Nat10 antibacterial peptide, a coding sequence and use and a preparation method thereof, and relates to a method based on multiomics, a biological big data based on multiomics data of bocachito, screening and identifying an antibacterial peptide precursor gene sequence, and obtaining an amino acid sequence of the bocachito Nat10 antibacterial peptide through translation design, as shown in SEQ ID NO: 3. Through activity simulation prediction and in-vitro experiment verification, the bocachito Nat10 antibacterial peptide shows inhibitory effects on the growth activities of Streptococcus agalactiae, Salmonella enteritidis, Staphylococcus aureus, Vibrio anguillarum and Escherichia coli, especially on Staphylococcus aureus, and shows the best antibacterial effect at a concentration of 2.5 micromoles per liter. The bocachito Nat10 antibacterial peptide can be used for preparing various bactericidal preparations, including bacteriostatic agents, medicines or additives, and has good practical value and social ecological benefits.

The application discloses a recombinant strain and a preparation method thereof and application of the recombinant strain in preparation of a vaccine for Streptococcus agalactiae of tilapia, and the recombinant strain is successfully constructed by the following steps: designing an ORF4 primer, amplifying an ORF4 gene fragment from a DNA template of Streptococcus agalactiae, editing the ORF4 gene fragment into Escherichia coli by means of a CRISPR / Cas9 gene editing technology, and connecting a green fluorescent protein (GFP). The recombinant strain is subjected to immunoprotection research on the Streptococcus agalactiae of tilapia, and it is shown that the recombinant strain has a good protection effect, and can provide a solid theoretical basis and technical support for application and development of the vaccine for Streptococcus agalactiae of tilapia in the field of aquaculture.

The present application relates to the field of biotechnology, and more particularly to a SNP marker related to the level of anti-streptococcus agalactiae IgM antibody of tilapia and application thereof. The present application screens out QTLs, functional genes and key signal pathways significantly related to the level of anti-streptococcus agalactiae IgM antibody of tilapia by RNA-Seq and BSA-Seq technologies, and further identifies two SNP markers closely related to the level of anti-streptococcus agalactiae IgM antibody of tilapia, thereby providing important genetic targets and tools for molecular marker-assisted breeding of anti-streptococcus agalactiae of tilapia.

The invention discloses a bifidobacterium animalis subsp. Lactis BT-G9 with a growth promoting function and application of the bifidobacterium animalis subsp. Lactis BT-G9, the bifidobacterium animalis subsp. Lactis BT-G9 is preserved in China Center for Type Culture Collection, the preservation date is November 20, 2025, and the preservation number is CCTCC NO: M 20252626. The brand new bifidobacterium animalis subsp. Lactis BT-G9 provided by the invention has good tolerance to gastric juice and intestinal juice, is suitable for survival in gastrointestinal tracts, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter kirscheri, streptococcus agalactiae and / or propionibacterium acnes. Experimental results show that the strain can promote animal growth and development and improve the autism, especially when the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 are combined for use, the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 have a synergistic effect, and the improvement effect on the autism can be remarkably improved. In addition, the extracellular vesicles prepared from the strain can effectively repair the skin barrier function.

The application belongs to the technical field of biological medicine, and particularly relates to application of pantothenic acid or a pharmaceutically acceptable salt thereof in preparation of a medicine for enhancing sensitivity of pathogenic bacteria to daptomycin. It is found for the first time that addition of pantothenic acid or a pharmaceutically acceptable salt thereof can improve the sensitivity of gram-positive bacteria including Staphylococcus aureus, Streptococcus agalactiae and Corynebacterium diphtheriae to daptomycin, significantly improve the bactericidal effect, and further research shows that pantothenic acid or a pharmaceutically acceptable salt thereof can promote the clearance, formation and reduction of pathogenic bacteria biofilm by daptomycin. The finding opens up a new way for overcoming antibiotic resistance and optimizing anti-infection treatment strategies.

The present application relates to the field of microbial technology, in particular to bacillus subtilis BS-1 and its application in water buffalo silage feed, the strain BS-1 of the present application has good bacteriostatic activity on escherichia coli, salmonella and streptococcus uberis, after mixing and fermenting according to a specific proportion with orange peel and cassava residue, the bacteriostatic spectrum of the obtained silage feed is significantly enhanced, which can simultaneously inhibit escherichia coli, campylobacter jejuni, salmonella, streptococcus uberis, staphylococcus aureus and streptococcus agalactiae that cause diarrhea and mastitis. In the feed, after mixing 60%-75% of orange peel and 25%-40% of cassava residue, the crude protein content of the fermentation product is significantly improved, and the fiber content is reduced. Feeding test shows that the feed can significantly improve the milk yield and milk quality of lactating water buffalo, and effectively alleviate diarrhea. The present application provides a safe, efficient and nutritious silage feed with disease prevention function.

A bacteriophage lytic enzyme and its application. The name of the bacteriophage lytic enzyme is PlyNJ3; the gene fragment encoding the lytic enzyme PlyNJ3 is amplified from streptococcus suis by PCR, and a prokaryotic expression vector plasmid pET32a-PlyNJ3 containing the PlyNJ3 gene is constructed, the recombinant plasmid is obtained by transforming DH5 alpha competent cells, and the protein is massively expressed in an escherichia coli expression system. Then, the lytic enzyme PlyNJ3 is purified by affinity purification medium, the high-efficiency expression of the lytic enzyme PlyNJ3 in vitro is realized, and the lytic effect of the lytic enzyme PlyNJ3 on different serotypes of streptococcus suis, streptococcus agalactiae and other common streptococci is verified in vitro. The bacteriophage lytic enzyme PlyNJ3 prepared by the application can selectively lyse target pathogenic bacteria, and has a good application prospect in the development of new bacteriophage drugs.

The present application relates to the field of aquaculture technology, in particular to a tilapia nilotica ferritin, a preparation method and application thereof, and a bacteriostatic agent.The amino acid sequence of the tilapia nilotica ferritin is shown as SEQ ID No.1, and the tilapia nilotica ferritin can inhibit Streptococcus agalactiae and / or Aeromonas hydrophila.The present application provides the tilapia nilotica ferritin, and in-vitro experiments have proved that the recombinant protein can effectively inhibit the proliferation of pathogenic bacteria.Further in-vivo experimental results show that the ferritin heavy chain (tilapia nilotica ferritin) has the important functions of inhibiting the proliferation of pathogenic bacteria and improving the survival rate of the organism, and plays an important role in the immune protection of the organism.

The application belongs to the technical field of Chinese herbal medicines, and particularly relates to a Chinese herbal medicine composition for resisting Streptococcus agalactiae, a preparation method and application thereof. Raw materials for preparing the Chinese herbal medicine composition include cortex mali and cumin. The Chinese herbal medicine composition is easy to obtain and simple to prepare, has no chemical residues, is not prone to drug resistance, has significant bacteriostatic activity on Streptococcus agalactiae, and can be applied to the prevention and treatment of Streptococcus agalactiae disease of fish such as tilapia.

The invention discloses a condom added with sophocarpidine hyaluronic acid lubricating liquid and a preparation method of the condom, and belongs to the technical field of condom production. The core of the method is that after matrine is dissolved, the matrine is added into hyaluronic acid lubricating liquid for the condoms, the hyaluronic acid lubricating liquid containing the matrine is prepared through stirring and mixing, the concentration of the matrine in the hyaluronic acid lubricating liquid is 7.7-25.0 mg / g, when the condoms are subjected to inner packaging, the matrine-containing lubricating agent is added into the condoms, and when the condoms are subjected to inner packaging, the matrine-containing lubricating agent is added into the condoms. And preparing the condom added with the sophocarpidine-containing hyaluronic acid lubricating liquid. According to the condom, inflammation generated after vaginal epithelial cells are stimulated by bacterial structural components is improved through matrine, and the common pathogenic bacteria such as staphylococcus aureus, escherichia coli, enterococcus faecalis and streptococcus agalactiae of vaginitis are inhibited in the using process; and the up-regulation level of NF-kB phosphorylation generated after lipopolysaccharide and peptidoglycan stimulate vaginal epithelial cells is relieved.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The application discloses a tilapia Npy antibacterial peptide, a coding sequence, and a use and a preparation method thereof, and relates to the following technical scheme: based on a multi-omics method, an antibacterial peptide precursor gene sequence is screened and recognized from a tilapia multi-omics data set based on biological big data, and then the tilapia Npy antibacterial peptide amino acid sequence is obtained through translation design, as shown in SEQ ID NO: 3; through activity simulation prediction and in-vitro experiment verification, the tilapia Npy antibacterial peptide shows inhibitory activity to gram-positive streptococcus agalactiae, staphylococcus aureus and gram-negative escherichia coli, especially to streptococcus agalactiae and staphylococcus aureus, and shows good antibacterial effect at a low concentration (2.5 μmol / L), and can be used for preparing antibacterial products, including preparation of an antibacterial agent, preparation of a medicine or preparation of an additive, and has good practical value and social ecological benefits.

The present application relates to oligosaccharide composition and its use. The present application particularly relates to the use of oligosaccharide composition in the preparation of products for preventing and / or treating aquaculture diseases caused by Vibrio parahaemolyticus, Vibrio harveyi and Streptococcus agalactiae, wherein the oligosaccharide composition is obtained by degrading polygalacturonan or pectin by a polygalacturonase as shown in SEQ ID No: 1, under the conditions of a polygalacturonase concentration of 0.045 mg / mL to 0.055 mg / mL, a polygalacturonan concentration of 7% to 9%, and a degradation time of 12 hours to 20 hours. The present application also relates to the use of oligosaccharide composition in aquaculture. The oligosaccharide composition of the present application has good bacteriostatic effect and disease prevention and control effect in aquaculture.

The invention belongs to the technical field of antibiotic enzymes, and relates to a recombinant antibiotic enzyme PlyTC37 as well as a coding gene and application thereof. The amino acid sequence of the recombinant antibiotic enzyme PlyTC37 is as shown in SEQ ID NO. 1, and the coding nucleotide sequence of the recombinant antibiotic enzyme PlyTC37 is as shown in SEQ ID NO. 2. The recombinant antibiotic enzyme PlyTC37 disclosed by the invention has a wider bactericidal spectrum, so that the recombinant antibiotic enzyme PlyTC37 has a killing effect on gram-negative bacteria such as acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa and gram-positive bacteria such as staphylococcus aureus, streptococcus agalactiae and streptococcus hemolyticus, the MIC value of the recombinant antibiotic enzyme PlyTC37 to acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa is about 20 [mu] g / ml. Meanwhile, the recombinant antibiotic enzyme PlyTC37 enables the load of acinetobacter baumannii, klebsiella pneumoniae, escherichia coli, salmonella and pseudomonas aeruginosa to be reduced by 4-5 logarithmic units in the presence of NaCl with physiological concentration, so that the clinical application prospect of the recombinant antibiotic enzyme PlyTC37 is remarkably improved.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The invention relates to the technical field of disease prevention and control of aquatic animals, and particularly discloses a fermented traditional Chinese medicine composition for resisting tilapia streptococcus agalactiae and a preparation method and application thereof.The fermented traditional Chinese medicine composition is obtained by fermenting the following traditional Chinese medicine raw materials in parts by weight: 1.2-5 parts of radix scutellariae, 0.5-2.5 parts of fructus chebulae and 0.5-1 part of radix et rhizoma rhei. The preparation method comprises the following steps: adding the traditional Chinese medicine raw materials into a fermentation culture medium in parts by weight, then inoculating a mixed fermentation bacterial solution, and carrying out fermentation culture in an environment of 35-39 DEG C, so as to obtain the fermented traditional Chinese medicine composition for resisting tilapia streptococcus agalactiae after fermentation is completed. The proper traditional Chinese medicine raw material combination is selected and fermented, and the survival rate of the tilapia infected with streptococcus agalactiae can be remarkably increased through test evaluation.

The invention discloses lactobacillus acidophilus BT-C15 with inflammation relieving and mucosal barrier repairing functions and application of the lactobacillus acidophilus BT-C15, the lactobacillus acidophilus BT-C15 is preserved in the China Center for Type Culture Collection, the preservation date is November 20, 2025, and the preservation number is CCTCC NO: M 20252625. The invention provides a brand new lactobacillus acidophilus BT-C15 which mainly has the effects of relieving inflammation and whitening the skin. The lactobacillus acidophilus BT-C15 has good tolerance to gastric juice and intestinal juice, is high in cell adhesion capacity, is suitable for survival in gastrointestinal tracts, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter Korotkoff, streptococcus agalactiae and / or propionibacterium acnes. Experimental results show that the strain can improve colitis, fade spots, whiten skin and improve autism, especially when the lactobacillus acidophilus BT-C15 and the bifidobacterium animalis subsp. Lactis BT-G9 are used in a combined mode, the lactobacillus acidophilus BT-C15 and the bifidobacterium animalis subsp. Lactis BT-G9 have a synergistic effect, and the improvement effect on the autism can be remarkably improved.

A method for rapidly identifying highly virulent strains of Streptococcus agalactiae, comprising: using a laser confocal Raman spectrometer to collect single-cell Raman spectra of clinical strains, and establishing a database; classifying data of III / ST17-type highly virulent GBS strains into a first group, named as GBS-HIGH, data of non-III / ST17-type GBS strains into a second group, named as GBS-OTHERS, and data of Escherichia coli into a third group, named as ECO; randomly dividing the three groups of data into a training set, a validation set and a test set in a ratio of 7:1:2; and on the basis of a ResNet18 residual neural network architecture, changing 2D convolution in a network to one-dimensional (1D) convolution suitable for a 1D Raman spectrum, determining optimal parameters by means of simulation experiments, training the weight of a model in the training set, and then selecting optimal hyperparameters by means of a result of the model on the verification set, so as to determine a trained model.

The application discloses a kind of nanobody targeting streptococcus agalactiae SIP protein and preparation and application thereof, it is related to biotechnology field, and the nanobody that the present application is screened by nanobody phage library construction, phage screening technology, and is efficiently and specifically combined with SIP protein Nanobody, the nanobody of streptococcus agalactiae SIP protein includes VHH fragment, with the amino acid sequence shown in SEQ ID NO:1.The nanobody can be combined with streptococcus agalactiae SIP protein high specificity, and the antibody can be targeted to SIP protein by the antibody, and the application discloses a kind of nanobody targeting streptococcus agalactiae SIP protein can be applied to fish disease diagnosis and treatment.

The invention discloses a method for screening crRNA based on molecular docking and application of double crRNA in improving group B streptococcus detection. A specific virulence gene in a streptococcus agalactiae genome is taken as a target spot, two potential crRNA candidates with the best detection effect are designed and screened out, and a double crRNA enhanced CRISPR detection system is established and is combined with RPA (recombinase polymerase amplification) amplification to be used for rapid and high-sensitivity detection of streptococcus agalactiae. The detection kit can complete detection from a sample to a result within one hour, the quantitative detection linear range is 103-107 cfu / mL, and the detection limit can reach 101 cfu / mL.

The present application belongs to the technical field of genetic engineering, and particularly relates to a Streptococcus agalactiae Mu-20 and a construction method and application thereof. The present application constructs a fish-derived Streptococcus agalactiae strain with a capsule polysaccharide deficiency, no hyaluronidase activity, no hemolysis and no trehalose fermentation, and the strain number is Mu-20. The strain was preserved in the Guangdong Microbial Culture Collection Center on June 13, 2022, and the preservation number is GDMCC No: 62540. The strain does not carry a chloramphenicol resistance marker gene, has high biological safety, has no risk of virulence returning to strength, has high immunogenicity, can protect immunized fish against the invasion of Streptococcus agalactiae, and is easy to cultivate, simple to use and low in production cost. The strain involved in the present application can be used to prepare a live attenuated vaccine for fish streptococcosis, and has extremely high commercial application value.

The invention discloses lactobacillus crispatus GG77 capable of repairing mucosal lesion and preventing pathogenic bacterium infection and application of the lactobacillus crispatus GG77, the lactobacillus crispatus GG77 is preserved in the China Center for Type Culture Collection, the preservation date is November 21, 2025, and the preservation number is CCTCC NO: M 20252646. Compared with the prior art, the invention provides a brand-new lactobacillus crispatus GG77 which mainly has the effects of repairing mucosal lesion and preventing pathogenic bacterium infection. The lactobacillus crispatus GG77 has high acid resistance, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter Korotkoff, streptococcus agalactiae and / or enterobacter cloacae. Experimental results show that the lactobacillus crispatus GG77 can repair mucosal lesion, prevent vaginitis recurrence, recover genital tract flora and promote calcium ion transport and absorption. Particularly, when the lactobacillus crispatus GG77 and the Witzia clostridium CN365 are combined for use, the lactobacillus crispatus GG77 and the Witzia clostridium CN365 have a synergistic effect, and the effect of transferring and absorbing calcium ions can be remarkably improved.

The invention discloses a freeze-dried reagent ball special for streptococcus agalactiae CRISPR detection aiming at a tilapia mossambica tissue matrix and application of the freeze-dried reagent ball, and belongs to the field of molecular diagnosis technology and on-site rapid detection of aquatic diseases. The freeze-drying reagent ball is a three-layer spherical freeze-drying body comprising an inner core layer, an isolating layer and a shell layer, the inner core layer contains an RAA amplification component aiming at a streptococcus agalactiae cfb gene, the shell layer contains a CRISPR-Cas12a detection component and a special anti-inhibition buffer system, and the isolating layer is a solid freeze-drying material layer of which the dissolution rate is slower than that of the shell layer. Through the dissolution time sequence control of the three-layer structure, the automatic sequence that an outer shell layer firstly dissolves and neutralizes an inhibitor and presets a detection system and an inner core layer then dissolves and starts amplification is realized, and multi-step reaction is integrated into one-step closed tube operation. During detection, only tilapia tissue crude extract needs to be added, and a result is interpreted through fluorescence after constant-temperature incubation. The method effectively overcomes the problems of aquatic product tissue matrix inhibition, unstable operation of an existing single-tube method and on-site pollution risk, and is high in sensitivity, extremely simple to operate and stable at normal temperature.

The invention provides streptococcus equi and application thereof in streptococcus equi gene editing, aims to improve the endogenous gene editing efficiency of a system on streptococcus equi, and relates to the technical field of bioengineering. According to the method, by introducing a streptococcus agalactiae RecT recombinase system, the editing efficiency of a streptococcus equi CRISPR-Cas9 gene editing system for high-yield HA is improved, and the problem that a streptococcus equi genome editing tool is low in efficiency is solved.

Disclosed are nucleic acid oligomers, including amplification oligomers and detection probes, for detection of Group B Streptococcus (GBS; Streptococcus agalactiae) nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.

This invention discloses a triplet real-time PCR detection method for Streptococcus agalactiae, Streptococcus dolphinus, and Lactococcus gasseri. It utilizes three primer sets and probes: one for Streptococcus agalactiae, one for Streptococcus dolphinus, and one for Lactococcus gasseri. By optimizing the degradation temperature, primer dosage, and probe dosage, this invention effectively reduces the mutual interference of the three target pathogens, improving the accuracy of the detection results. This detection method has significant application value in fish farming. The reagent kit of this invention has low preparation cost, a simple preparation process, and is easily scalable for industrial production, thus possessing broad market prospects.

The present invention relates to compositions and methods to detect Group B Streptococcus (GBS, Streptococcus agalactiae) and to identify the most prevalent genes responsible for clindamycin resistant GBS such as ermB, ermTR, ermT, lsaC and lsaE by a multiplex real-time PCR assay.